DDX5 promotes oncogene C3 and FABP1 expressions and drives intestinal inflammation and tumorigenesis.
Abstract
Tumorigenesis in different segments of the intestinal tract involves tissue-specific oncogenic drivers. In the colon, complement component 3 (C3) activation is a major contributor to inflammation and malignancies. By contrast, tumorigenesis in the small intestine involves fatty acid-binding protein 1 (FABP1). However, little is known of the upstream mechanisms driving their expressions in different segments of the intestinal tract. Here, we report that the RNA-binding protein DDX5 binds to the mRNA transcripts of <i>C3</i> and <i>Fabp1</i> to augment their expressions posttranscriptionally. Knocking out DDX5 in epithelial cells protected mice from intestinal tumorigenesis and dextran sodium sulfate (DSS)-induced colitis. Identification of DDX5 as a common upstream regulator of tissue-specific oncogenic molecules provides an excellent therapeutic target for intestinal diseases.
Publication Types
Keywords
MeSH Terms
Funding
Linked Datasets (2)
DDX5 promotes oncogene C3 and FABP1 expressions and drives intestinal inflammation and tumorigenesis
Mus musculus8 data files
| File | Type | Size |
|---|---|---|
| NA01_S1_L008_R1_001.fastq.gz | RNA-Seq | 3.7 GB |
| NA02_S2_L008_R1_001.fastq.gz | RNA-Seq | 1.7 GB |
| NA03_S3_L008_R1_001.fastq.gz | RNA-Seq | 2.4 GB |
| NA04_S4_L008_R1_001.fastq.gz | RNA-Seq | 2.8 GB |
| NA05_S5_L008_R1_001.fastq.gz | RNA-Seq | 2.8 GB |
| NA06_S6_L008_R1_001.fastq.gz | RNA-Seq | 3.0 GB |
| NA07_S7_L008_R1_001.fastq.gz | RNA-Seq | 3.2 GB |
| NA08_S8_L008_R1_001.fastq.gz | RNA-Seq | 2.9 GB |
DDX5 targets tissue specific RNAs to promote intestine tumorigenesis
Mus musculus12 data files
| File | Type | Size |
|---|---|---|
| INPUT_G1_S36_L003_R1_001.fastq | RIP-Seq | 1.5 GB |
| INPUT_G2_S38_L003_R1_001.fastq | RIP-Seq | 2.0 GB |
| IP_G1_S37_L003_R1_001.fastq | RIP-Seq | 1.5 GB |
| IP_G2_S39_L003_R1_001.fastq | RIP-Seq | 736.2 MB |
| mAb_IN_1_Ep_S35_L003_R1_001.fastq.gz | RIP-Seq | 550.5 MB |
| mAb_IN_2_Ep_S37_L003_R1_001.fastq.gz | RIP-Seq | 695.1 MB |
| mAb_IP_1_Ep_S36_L003_R1_001.fastq.gz | RIP-Seq | 746.7 MB |
| mAb_IP_2_Ep_S38_L003_R1_001.fastq.gz | RIP-Seq | 533.2 MB |
| rAb_IN_1_Ep_S39_L003_R1_001.fastq.gz | RIP-Seq | 631.1 MB |
| rAb_IN_2_Ep_S41_L003_R1_001.fastq.gz | RIP-Seq | 623.4 MB |
| rAb_IP_1_Ep_S40_L003_R1_001.fastq.gz | RIP-Seq | 457.5 MB |
| rAb_IP_2_Ep_S42_L003_R1_001.fastq.gz | RIP-Seq | 547.6 MB |
Potentially Related Datasets (9)
These accessions were text-mined from the PMC full text. They may be referenced for comparison, cited from other studies, or otherwise mentioned without being primary data for this paper.
Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients
Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples)
Gene Expression Profiles in Stage II and III Colon Cancer. Application of a 128-gene signature
Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery
A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III.